VI International Summit
Heart Failure and Pulmonary Hypertension Management in the Polypharmacy and Device Era
Heart Failure Review 2021
Liotta Symposium
November 29 - December 04, 2021
Alejandro Barbagelata, MD, FAHA, FSCAI, FICA, MSAC
Program Director
Dr. Barbagelata is an invasive cardiologist with Heart Failure longstanding expertise. He was past director of the Heart failure, assist devices and Transplant at University of Texas medical branch. Professor of Medicine/Cardiology Duke University School of Medicine and Board of Directors of DUCCS (Duke University Cardiovascular Society). Member of the International Speaker Bureau of the American Heart Association. He Co-direct the Heart Failure program at the Catholic University and has privileges in several centers in private practice.
JOHN MC MURRAY
New Trials in Heart Failure.Where are we at the end of 2020
DAVID BARAN
Cardiogenic Shock
Sergio V. Perrone, MD, MTFACC, MTSACD
Program Director
Dr. Perrone was instrumental in generating the largest Heart Failure and Transplant program in South America in the early 80s and is an opinion leader in the region. He co-direct the heart failure program at the Catholic University and direct the Heart Failure and Pulmonary Hypertension Journal. He is the advisor in Heart Failure in a lot of Institutes in Argentina and in other South American Countries
JOHN CLELAND
Iron Deficiency in Heart Failure
MILTON PACKER
Quadruple Therapy as the new standard of care in heart failure with reduced EF
JOSEPH ROGERS
VAD-Destination Therapy or Bridge?
BUD FRAZIER
Ventricular Assist Devices. Present and future
PILAR ESCRIBANO
pre and post capillary pulmonary hypertension. upfront therapy?
STEFAN ANKER
Drug and devices in the treatment of hfpef. new options
ROBERT MENTZ
With arnis and sglt2, how can we manage polipharmacy in hf?
MARCELO DI CARLI
How imaging change the treatment paradigm in cardiomyopathies
Richard krasuski
support in pulmonary hypertension in advanced right heart failure
Carlos morillo
End stage hf patients keep need to keep or remove CRT-d?
Shelley Zieroth, MD
Past President Canadian Heart Failure Society
